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Highlights 
 Toxins that target the nervous system are structurally and functionally diverse. 
 Many toxins display exquisite selectivity for neuronal ion channels and receptors. 
 These toxins have proved to be useful tools to probe neuronal function. 
Abstract  
Toxins have been used as tools for decades to study the structure and function of neuronal ion 
channels and receptors. The biological origin of these toxins varies from single cell organisms, 
including bacteria and algae, to complex multicellular organisms, including a wide variety of 
plants and venomous animals.  Toxins are a structurally and functional diverse group of 
compounds that often modulate neuronal function by interacting with an ion channel or 
receptor. Many of these toxins display high affinity and exquisite selectivity, making them 
valuable tools to probe the structure and function of neuronal ion channels and receptors. This 
review article provides an overview of the experimental techniques used to assess the effects 
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that toxins have on neuronal function, as well as discussion on toxins that have been used as 
tools, with a focus on toxins that target voltage-gated and ligand-gated ion channels.  
Keywords : Toxins; pharmacology; neuronal; voltage-gated ion channel; ligand-gated ion 
channel; receptor.  
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1. Introduction  
In this review, we use the term ‘toxin’ broadly to include any small molecule or peptide of 
biological origin that has activity on neuronal ion channels or receptors, regardless of the route 
of exposure. This includes ‘poisons’, which are toxins that are ingested or absorbed, and 
‘venoms’, which are toxins that are injected. It should be noted that all compounds can be 
considered toxic, and that it is the dose that determines toxicity, a concept first devised by 
physician Paracelsus in the 16th century. Therefore, neurotoxins are generally distinguished by 
their ability to bind to a neuronal ion channel or receptor with relatively high affinity (in the 
nanomolar to micromolar range). 
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The biological origins of toxins discussed in this review are diverse, ranging from single cell 
organisms, such as bacteria and algae, to multicellular organisms, which includes plants and 
animals. These toxins may be produced to deter predators, such as capsaicin produced by chilli 
peppers, or used to capture prey, as is the case for most venom-producing animals such as 
spiders, snakes, scorpions and cone snails. It is therefore not surprising that toxins that target 
the nervous system have independently evolved many times over in numerous plant and animal 
species. They modulate neuronal functions in many ways, generally leading to the disruption 
of normal electrical activity or chemical messenger signalling. Many of these toxins display 
high affinity and selectivity for a particular molecular target, making them useful 
pharmacological tools to probe neuronal ion channel and receptor function. However, it should 
be noted that even toxins lacking exquisite selectivity are still useful pharmacological tools, 
with numerous examples of toxins in the literature used to discover novel ion channel subtypes, 
improve our understanding of ion channel structure-function relationships, and identify novel 
allosteric binding sites, all of which provide essential insights for the rational design of more 
selective probes in the future. In addition, toxins can be used to identify novel therapeutic 
targets, with the most notable example being the ω-conotoxins establishing CaV2.2 as a novel 
therapeutic target for the treatment of neuropathic pain.    
The aim of this review is to provide an overview of the techniques commonly used to assess 
the effects that toxins have on neuronal function (Figure 1), to provide notable examples of 
toxins that have been used in the literature as tools to fingerprint neuronal pharmacology, and 
to discuss the limitations of using toxins as tools.   
2. Techniques for assessing neuronal function 
2.1 Patch-clamp electrophysiology 
One of the most common experimental techniques for assessing neuronal function is 
electrophysiology.  In these experiments the electrical properties of neurons, associated with 
the flow of ions, are probed using micropipettes [125]. The principles of electrophysiology are 
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used to study both intracellular and extracellular properties of cells. Furthermore, emerging 
technology such as planar patch clamp and multi-electrode array platforms continue to enhance 
our understanding of neuronal function in a high-throughput manner [130, 165]. In practice, 
neurons isolated in culture, in ex vivo slices (eg. brain, spinal cord) or in vivo are probed with a 
small pipette filled with a solution similar to the intracellular contents [55, 188]. In general, for 
whole-cell patch clamping after generation of a “gigaseal” between the cell membrane and the 
patch pipette, the cell membrane is breached allowing access between the intracellular 
electrolyte and the recording electrode. Resulting information is then compared to a reference 
electrode in the extracellular solution. In this configuration, neurons can be “clamped” for 
voltage or current, measuring the trans-membrane ionic current or membrane voltage, 
respectively. Many variations on this protocol have been devised including perforated patch, 
inside-out, and outside-in, however the principles of micropipette, reference and recording 
electrode set-up remain largely the same [81]. The use of different intracellular and extracellular 
solution combinations allows the experimenter to isolate particular membrane-spanning 
channels, and the use of temperature control devices whilst recording increases the scope of 
electrophysiology, contributing to the discovery of temperature sensitive channels [69]. 
Electrophysiology has and continues to be the gold standard for assessing the pharmacological 
effects of toxins on ion channels [137, 142]. Toxins are perfused or added to the intracellular 
or extracellular recording solutions and the subsequent effect on ion channel biophysical 
properties are studied.  
2.2 Calcium imaging    
Calcium imaging remains a robust tool for assessing neuronal function. The influx of calcium 
via a number of different membrane bound channels tightly controls many intracellular 
processes [124]. Calcium imaging requires calcium indicators, including Fura-2 and Fluo-4, 
which exhibit changes in fluorescence upon the binding of calcium ions [174]. Neurons, in 
vitro, ex vivo or in vivo, with an indicator present are excited at appropriate wavelengths and 
captured by fluorescence microscopy using a charge coupled device (CCD) camera in real time 
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[76]. Using this technique, toxin molecules can be perfused directly onto neurons to assess 
effects on Ca2+ permeability.  Toxins may act directly on Ca2+ permeable channels or cause 
perturbations in intracellular Ca2+ levels via second messenger systems. Crucially, calcium 
imaging gives the user the ability to visualise more than one neuron at a time, and thus neuronal 
subpopulations can be identified based on functional response. Indeed toxins have been used in 
this manner to assess subpopulation-specific responses in a high-content approach known as 
“constellation pharmacology” [169]. This technique uses the selective nature of toxins to 
identify constellations of receptor and channel types functionally expressed on single or 
populations of neurons [43]. 
2.3 Single-Fiber Recordings  
The rodent saphenous skin-nerve preparation is a valuable technique used to study responses 
of individual primary sensory neurons to mechanical, thermal and/or chemical stimuli [50, 
148]. In this method, the saphenous nerve along with the skin of the dorsal hind paw and lower 
leg is removed and placed in an organ bath chamber. The proximal end of the saphenous nerve 
is placed in a separate recording chamber and immersed in paraffin oil. To obtain a single-fiber 
recording, the nerve is desheathed and teased apart until mechanical probing identifies a single 
receptive field on the skin. The fiber is then classified based on conduction velocity (C-fiber < 
1 m/s, A-fiber 1.6-12 m/s), mechanical von Frey threshold (low threshold 1-5.7 mN, high 
threshold 5.7-128 mN), and responsiveness to cold and heat [195]. The technique can be used 
to study the role of specific ion channels or receptors on neuronal excitability using transgenic 
mice or selective compounds, including toxins. To test the effect of a toxin, the receptive field 
on the skin is isolated with a ring to allow continual perfusion of the toxin to the peripheral 
nerve terminal. Spontaneous activity and responses to mechanical, cold and/or heat stimuli can 
then be compared before and after the addition of a toxin. A similar methodology is employed 
in transgenic mice, however due to the heterogeneity of primary sensory neurons; a much larger 
sample size is needed. 
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2.4 Compound Action Potential Recordings  
Compound action potential (CAP) recordings are used to study the electrical conduction 
properties of a whole nerve, with the sciatic nerve commonly used in studies assessing 
cutaneous primary sensory neurons. In this method, a nerve segment is isolated and mounted 
between two suction electrodes: one that delivers electrical stimuli and one that records the 
signal [96]. An electrical stimulus is required to synchronize action potentials, as asynchronous 
action potentials cannot be recorded from a whole nerve [80]. The CAP waveform shape, 
amplitude and latency of A- or C-fibers can then be compared before and after perfusion of a 
selective compound to the axon. When testing toxins, it may be necessary to desheath the nerve, 
as some toxins cannot cross the perineurium [78].  
2.5 Neurotransmitter Release 
The release of neurotransmitters is an important neurological mechanism for communication 
between neurons. Changes in release of neurotransmitters can be indicative of a 
pharmacological response to a drug or toxin, of pathology such as with Parkinson’s disease or 
addiction or can be a sign of neuronal plasticity. Measuring the neurotransmitter release is an 
important technique and some of the commonly used methods are provided below. 
Microdialysis is a minimally invasive method to measure neurotransmitter and other mediator 
release in vivo [187].  The microdialysis equipment generally comprises of a tubular 
semipermeable dialysis membrane that is inserted into the anatomical region to be sampled. An 
exogenous physiological solution is perfused along the membrane and the analyte of interest is 
able to cross from the tissue through the membrane by following the concentration gradient. A 
slow flow rate of the exogenous physiological fluid allows for the analyte to cross and come to 
equilibrium with the sampled tissue.   Samples of perfusate are collected over periods of time 
and the concentrations of different neurotransmitters determined by using compound-optimized 
chromatography [35, 46]. This technique can analyse a wide array of neurotransmitters with 
high sensitivity. However due to relatively large volumes of sample required for quantification, 
measures of neurotransmitters are provided in blocks of time ranging from minutes to hours. 
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Electrochemical detection of neurotransmitters has been the primary method used in vivo. Fast 
scanning cyclic voltammetry is a technique that is commonly used to measure dopamine, but 
also other monoamines (5-HT, adrenaline and noradrenaline) release from neurons in situ tissue 
preparations and in vivo [88, 150, 167]. The technique consists of placing a carbon fiber 
microelectrode at the brain region of interest and a current sufficient to oxidise monoamines is 
passed through it. The oxidation of the monoamine neurotransmitters allows for current flow 
at the electrode, which is converted to a concentration by prior equilibration [88]. Fast scanning 
cyclic voltammetry provides exact measurements of neurotransmitter release in real time, from 
precise areas of the brain. The technique provides nanomolar to micromolar concentrations and 
each voltogramm cycles every 100 milliseconds providing resolution of tonic and phasic 
neurotransmitter release patterns [150].  
2.6 Neuron ablation 
Plant-derived toxins known as ribosome-inactivating proteins (RIPs), such as saporin from the 
seeds of Saponaria officinalis (soapwort), can be used as tools to selectively kill specific cell 
populations. They cause irreversible damage to ribosomes, which leads to the inhibition of 
protein synthesis and ultimately cell death [166]. The specificity comes by conjugation of RIPs 
to targeting proteins, such as antibodies, hormones, or ligands, enabling the RIP to internalise 
into the cell where it is active [138, 166]. This technique has been used extensively to target 
cancer cells by conjugation of an RIP to a monoclonal antibody that selectively binds to a cancer 
cell surface-specific antigen, with many ‘immunotoxins’ undergoing clinical trials [6, 139]. 
These axonally transported RIP toxins can also be used to ablate specific neuronal populations 
in vivo. This approach was used to ablate Neuropeptide Y (NPY) receptor expressing neurons, 
by conjugating NPY to saporin, which identified an important role for NPY receptor-expressing 
neurons in mediating anxiety behaviors [114]. Similarly, isolectin B4 (IB4), used to distinguish 
small-diameter sensory neurons into peptidergic (IB4-negative) and non-peptidergic (IB4-
positive), is routinely conjugated with saporin to assess the role of non-peptidergic neurons in 
nociception by targeted chemical removal [179, 183]. One intriguing possibility is RIPs 
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conjugated to venom-derived peptides, particularly those that display high level of specificity 
for their target (many of which described in detail below). Hypothetically, this would lead to 
highly specific ablation of certain neuronal subpopulations.  
2.7 Behavioral studies 
While the methods discussed above provide crucial insights into the molecular mechanisms 
underlying neuronal excitability, no method currently exists that can model an intact nervous 
system without using a whole animal. Therefore, in vivo experiments using electrophysiological 
recordings in anaesthetized animals or behavioral studies in awake, non-anaethetized animals 
have been developed. 
Animal models play a crucial role in defining animal behaviors and determining the role of 
receptors and neurological pathways in those behaviors.  Animal models of cognition [123], 
memory, reward [113], aversion [47] and decision making [131], along with models of 
pathology such as depression [133], addiction [113], dementia [123] amongst others have been 
essential in developing an understanding of the molecular mechanisms and neurological 
pathways that mediate them.  Determining the importance of specific brain regions and receptor 
subtypes in physiological and pathological conditions has been made possible through 
microinjection of specific pharmacological agents (often selective toxins) into regions of 
interest and measuring behavioral changes. Stereotaxic surgery allows the accurate insertion of 
cannulas into specific brain regions by the use of landmarks bregma and lambda on the skull in 
reference to the brain atlas [72, 136]. Once animals recover from their surgery, pharmacological 
tools can then be infused slowly into the brain region of conscious animals and their behavior 
determined. 
Animal models have also played a crucial role in our understanding of pain pathways, with 
mice and rats the most common species used in pain behavioral studies [120]. As pain cannot 
directly be measured in rodents, withdrawal of the hind paw or tail from a noxious mechanical, 
thermal, chemical or electrical stimulus is routinely used to quantify ‘pain-like’ behaviors [49]. 
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Increased or decreased nociception is then inferred based on the level of stimulus required to 
elicit a withdrawal response. This can be performed in naïve rodents or in rodents that have had 
a pain state induced by administration of a compound, tissue damage, inflammation or nerve 
injury. The role of specific ion channels or receptors in the sensation of noxious mechanical, 
thermal, chemical or (less commonly) electrical stimuli can then be assessed using transgenic 
mice or following administration of a selective compound, including toxins. For peripheral 
administration, toxins are routinely delivered by shallow subcutaneous injection into the hind 
paw (intraplantar injection), as this allows a high local concentration to be reached at sensory 
nerve endings and reduces the risk of systemic adverse effects [52]. For delivery to the central 
nervous system (CNS), toxins (particularly peptides) often require administration by intrathecal 
injection, intracerebroventricular injection, or microinjection into specific brain regions, as they 
generally cannot cross the blood-brain-barrier [23]. 
3. Toxins used as probes 
While there are likely hundreds of examples of toxins that have been used as tools to probe 
neuronal function in the literature, the aim of this review is not to provide an exhaustive list, 
but rather to provide the reader with examples of toxins that have made significant contributions 
to field of neuronal pharmacology. This review will focus on toxins that act on voltage-gated 
and ligand-gated ion channels; however there have also been a number of toxins identified that 
act at G-protein-coupled receptors [31, 51, 154].  
3.1 Voltage-gated ion channels 
3.1.1 Voltage-gated sodium channels 
Voltage-gated sodium channels (NaV) are pore-forming membrane proteins that permit the 
influx of sodium ions across cell membranes, a process that is essential for the generation and 
propagation of action potentials in electrically excitable cells. Because of this, numerous plants 
and animals have evolved toxins that target NaV channels for prey capture and/or predator 
defence, including cone snails, spiders, snakes, scorpions and sea anemone [21, 62, 97, 189]. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 10 
In mammals, nine different NaV channel subtypes (NaV1.1-1.9) have been described, with five 
subtypes (NaV1.1, 1.6, 1.7, 1.8, 1.9) expressed on adult peripheral sensory neurons [15, 70, 71]. 
Despite high sequence homology (>50%) between NaV subtypes [175], several toxins have 
been isolated that are selective for one or more NaV subtypes (see [85] for review), making 
them useful tools to probe NaV channel function. 
The most notable example is tetrodotoxin (TTX), produced by marine bacteria and 
bioaccumulated in puffer fish, which is widely used to differentiate NaV channels as either TTX 
sensitive (IC50 < 10 nM; NaV1.1, 1.2, 1.3, 1.4, 1.6, 1.7) or TTX resistant (IC50 > 1 μM; NaV1.5, 
1.8, 1.9) [85]. TTX is routinely used in patch-clamp electrophysiology on dorsal root ganglion 
neurons to isolate TTX resistant current, attributable to NaV1.8 and NaV1.9 [153]. TTX is also 
used in combination with NaV1.8 or NaV1.9 knockout mice to elucidate the specific contribution 
of these channels to neuronal excitability. This approach has identified NaV1.8 as the primary 
mediator of action potential propagation in the distal axonal segment of C-fibers using CAP 
recordings [96].  Application of TTX to the receptive fields of NaV1.8+/+ and NaV1.8-/- mice in 
the saphenous skin-nerve preparation has also identified NaV1.8 as the primary mediator of 
action potential generation at peripheral nerve terminals at low temperatures (10 °C) in C-fibers 
[196].  
The use of toxins has also been pivotal in elucidating the role of NaV1.6 in pain, as loss of 
functional NaV1.6 in Scn8amed/med mice results in the development of hind limb paralysis and 
premature death 21 days post partum, making the strain unsuitable for in vivo behavioral studies 
[26]. Intraplantar injection of μ-conotoxin GIIIA (NaV1.1/NaV1.6 inhibitor), but not TIIIA 
(NaV1.1/NaV1.2 inhibitor) [185], significantly reverses oxaliplatin- and ciguatoxin-induced 
cold allodynia in mice, suggesting a role for NaV1.6-expressing neurons as mediators of 
pathological cold pain in vivo [53, 194].  In line with this, intraplantar administration of the β-
scorpion toxin Cn2 in mice, a selective and potent NaV1.6 activator (EC50 39 nM) [156], causes 
spontaneous flinching, mechanical allodynia, and enhances 4-aminopyridine (KV channel 
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blocker) cold allodynia, providing further evidence for the involvement of NaV1.6 in peripheral 
pain pathways [53].  
A similar approach has also been used to identify a role for NaV1.1 in peripheral pain pathways. 
Application of δ-theraphotoxin-Hm1a, a selective and potent NaV1.1 activator (EC50 38 nM), 
to the receptive fields of A-fibers in the saphenous skin-nerve preparation leads to an increase 
in firing frequency in response to mechanical stimuli [132]. Consistent with an increase in 
mechanical excitability, intraplantar injection of δ-theraphotoxin-Hm1a also causes 
spontaneous pain behaviors and mechanical allodynia in mice, which are partially reversed in 
peripherin-Cre NaV1.1 conditional knockout mice [132].  
3.1.2 Voltage-gated potassium channels 
Voltage-gated potassium channels (KV) are pore-forming membrane proteins that permit the 
efflux of potassium ions across cell membranes, influencing action potential threshold, 
waveform and frequency. As such, numerous species have evolved toxins that target KV 
channels, including scorpions, spiders, sea anemones, snakes and cone snails [129]. In 
mammals, forty different KV α-subunits have been described to date, which are grouped into 
twelve subfamilies (KV1.x-KV12.x) that combine to form either homo- or heterotetrameric 
channels, the composition of which can alter pharmacology [4]. Due to the number of KV α-
subunits, which is further complicated by the number of possible tetrameric combinations, 
determining the activity of toxins across all KV channels is arduous and typically not performed. 
Despite this, several toxins that target KV channels have been used as tools to study the role of 
KV channels in neuronal excitability. 
Dendrotoxins, from the venom of both the green and black mamba snakes, are potent inhibitors 
of KV1.1, KV1.2 and KV1.6 [79], and have been used as pharmacological tools for decades to 
inhibit slowly inactivating or delayed rectifier potassium currents (IDR) in both the central and 
peripheral nervous system. The important role of KV1.1 and KV1.2 in regulating CNS 
excitability was first revealed by administration of α-dendrotoxin in the brain of rats, which 
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caused spontaneous seizures [11], and was later confirmed by the development of spontaneous 
seizures in KV1.1 and KV1.2 knockout mice [25, 163].  In addition, α-dendrotoxin is commonly 
used with 4-aminopyridine to assess the contribution of IDR currents in trigeminal and dorsal 
root ganglion neurons [116, 190].  
BDS-I, isolated from the venom of the sea anemone Anemonia sulcata, is an inhibitor of KV3.1, 
KV3.2 and KV3.4 [59, 192]. BDS-I was recently used in combination with α-dendrotoxin and 
4-aminopyridine to identify KV3 channels as key contributors to spike repolarization in small 
capsaicin-sensitive dorsal root ganglion neurons [106]. While useful to probe KV3 channel 
function under patch-clamp conditions that isolate potassium current, caution should be used 
in interpreting the results obtained using BDS-I in other methods, as BDS-I was recently found 
to potently activate NaV1.7 [107].  
Ts8, isolated from the venom of the Brazilian yellow scorpion Tityus serrulatus, is an inhibitor 
of KV4.2 channels (IC50 313-652 nM), with no effect on NaV1.2, NaV1.4, NaV1.6, KV1.1-1.6, 
KV2.1, KV3.1, KV7.1, KV7.2, KV7.4, KV7.5 or KV10.1 at 1 μM [143]. Intraplantar injection of 
Ts8 (60 μM) in mice causes spontaneous pain behaviors and mechanical allodynia, revealing a 
role for peripheral KV4.2 in nociception. While mechanical allodynia is consistent with the 
phenotype present in KV4.2-/- mice, KV4.2 is also expressed in the brain and spinal cord [82]. 
Therefore, Ts8 is a useful tool to assess specific block of KV4.2 in periphery sensory neurons, 
as large peptide-based toxins are unlikely to cross the blood brain barrier, however Ts8 may 
have activity at other KV channels at the concentrations used to elicit pain behaviors in vivo.  
3.1.3 Voltage-gated calcium channels 
Voltage-gated calcium channels (CaV) are pore-forming membrane proteins that open in 
response to membrane depolarisation to permit the influx of calcium ions, which is essential 
for the regulation of many intracellular processes, including neurotransmitter release. Toxins 
that target CaV channels have been isolated from the venom of many species, including cone 
snails, spiders, scorpions and snakes [22]. In mammals, ten different CaV α-subunits have been 
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described, which are divided into three families (CaV1, CaV2 and CaV3), producing five distinct 
types of calcium currents in neuronal and non-neuronal tissues, known as L-type (CaV1.1-1.4), 
P/Q-type (CaV2.1), N-type (CaV2.2), R-type (CaV2.3) and T-type (CaV3.1-3.3) [33]. In 
combination with the dihydropyridines that selectively block L-type current, the venom-derived 
peptides ω-agatoxin IVA, ω-conotoxin GVIA, and SNX-482 (spider toxin), which selectively 
block P/Q-type current, N-type current, and R-type current, respectively, have proved to be 
useful tools in the isolation of CaV currents [3, 44]. Most noteworthy, the ω-conotoxins have 
been pivotal in establishing CaV2.2 on the central terminals of primary sensory neurons as a 
therapeutic target for neuropathic pain, with the ω-conotoxin MVIIA (zinconotide, Prialt) 
currently approved by the FDA for the treatment of severe refractory pain by intrathecal 
injection [2].  
3.2 Ligand-gated ion channels 
3.2.1 Nicotinic acetylcholine receptors 
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand gated ion channels that are 
activated by the endogenous ligand acetylcholine and the exogenous ligand nicotine. The 
membrane ion channel is comprised of a combination of 5 subunits (subunits α1-10, β1-4 and 
γ, δ and ε), arranged around a pore, consisting of either a homomeric or heteromeric 
arrangement of subunits [5, 73, 94]. The arrangement of these subunits confers selectivity to 
various exogenous ligands. Acetylcholine and nicotine bind directly to the boundary between 
subunits (5 binding sites), stabilising the opened state of the channel allowing the passage of 
cations (Na+, K+ and sometimes Ca2+) through the pore [5]. Nicotinic receptors are found in the 
peripheral nervous system, at the neuromuscular junction and in the autonomic nervous system, 
as well as the CNS [5]. In the brain, activation of nAChRs commonly results in the release of 
neurotransmitters dopamine, serotonin, glutamate and γ-hydroxybutyric acid [5]. Neuronal 
nAChRs have a role in a number of pathological conditions including addiction [64], depression 
[119], Alzheimer’s disease, Parkinson’s disease [109] and various forms of epilepsy and 
schizophrenia [102].  
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3.2.1.1 Neuronal nAChR agonists 
A number of plants and animals have evolved selective toxins and venoms that can be utilised 
against predators or against their prey. Due to high levels of nAChR expression and their 
physiological importance within the nervous system, a number of defensive and predatory 
mechanisms have evolved in plants, animals and bacteria to both activate and inhibit nAChRs. 
These plants and animals have provided a diverse resource of pharmacological tools to study 
nAChRs. These tools have become particularly important, as antibodies for neuronal nicotinic 
receptors have been shown to lack specificity in knockout mice [122]. There are a number of 
toxins that have been identified that act on the nicotinic receptors at the neuromuscular junction, 
however this review will focus on the neuronal nAChR.  
Toxins that act on nAChRs have been historically used for medicinal, recreational and for 
execution purposes. Poison-Hemlock, an extract from Conium maculatum was famously 
described by Plato as the poisoned tea used to execute Socrates [149]. Poison hemlock contains 
a number of piperidine alkaloids with coniine and γ-coniceïne the most prevalent nAChR 
actives responsible for the plant’s toxicity [100, 101]. The most well-known nAChR toxin is 
nicotine from the nightshade family of plants, a toxin commercially produced from the 
Nicontania tobacum plant. In the late 16th century, the tobacco plant was used to treat various 
disorders from pain to parasites, while in the early 19th century extracted nicotine became one 
of the earliest toxins to be used as an experimental tool to provide evidence of the autonomic 
nervous system.  Nicotine has greatest affinity for the α4β2 nAChRs (low nanomolar), which 
is the predominant nAChR expressed in the brain, but also acts at α3β4 and α7 nAChR (high 
nanomolar to low micromolar) [87]. Radiolabelled nicotine is used as an agonist to determine 
receptor densities in healthy brains and in cases of pathology, however other agonists have been 
identified in more recent years that provide greater utility [14, 27]. There has been great interest 
in developing and identifying selective and non-selective nAChRs agonists for the treatment of 
various neurological conditions and as research tools to elucidate neurological mechanisms. 
Cytisine is an alkaloid partial agonist at β2 containing nAChRs and is found in plants from the 
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Leguminosae family. It has been shown to be effective in clinical trials for the treatment of 
nicotine addiction [182], and has also shown efficacy in animal models of other types of 
addiction and compulsive behavior [13, 159].  
While plants have provided an abundant source of nAChR agonists, a number of ligands have 
been found from other sources. Anatoxin-A is a bicyclic amine alkaloid neurotoxin produced 
by cyanobacteria of the Anabaena, Oscillatoria and Aphanizomenon (blue green algae) species 
amongst others. Anatoxin-A exerts its toxic effects primarily by binding irreversibly to and 
activating α4β2 nAChR [170]. Anatoxin-A is a potent agonist at the nicotinic receptors and has 
been used as a tool to elucidate the pharmacology of nAChRs [8, 67, 115] and to measure 
neurotransmitter release in vitro [29, 39] and in vivo [28].  Epibatidine is an alkaloid secreted 
on the skin of the Ecuadorian poison arrow frog (Epipedobates tricolor), and potently activates 
α4β2 and α3β4 nAChRs [68, 144]. Epibatidine binds to nAChRs with very high affinity and 
radiolabelled epibatine has been used to study the binding and conformational changes of 
nAChRs as well as changes to receptor subunit expression in disease states and brain regions 
[95, 145, 159]. The toxin has also been used to elucidate neurotransmitter release mechanisms 
[184] and has been used in animal models to demonstrate the role of  nAChRs in analgesia 
[144]. 
3.2.1.2 Neuronal nAChR antagonists 
Cone snails have developed a diverse array of short peptides for both hunting prey and defense 
against predators. Within their venom are a family of 12-19 amino acid disulphide bond 
stabilised peptides that are highly selective for nAChRs known as the α-conotoxins.  To date 
all cone snail venoms studied have been found to contain a nAChR inhibitor. One of the first 
neuronal nAChR antagonists identified was the α-conotoxin ImI, an α7 nAChR selective 
antagonist (with some activity at α9) [89]. Subsequently a range of other selective neuronal α-
conotoxins have been identified, including BuIA an α6 subunit nAChR selective antagonist [9], 
AuIB an α3β4 nAChR antagonist [112], PIA an α6 subunit-containing inhibitor [61], MII and 
PnIA α3β2 nAChR inhibitors [30], PnIB and Epl α7 nAChR antagonists [128], AnIB an α3β2  
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and α7 nAChR inhibitor [111], GIC an α3β2 and α6β2β3 nAChR antagonist, RgIa and Vc1.1 
potent nAChR α9α10 inhibitors [63, 177], and GID an α3β2, α7 and α4β2 nAChR inhibitor 
[127]. The α-conotoxins have played a pivotal role in nAChR pharmacology and have been 
used to elucidate nAChR subtype roles in different diseases. Some examples of how α-
conotoxins have been used as tools, include determining which subtypes are expressed within 
certain brain regions and how they change in animal models of addiction by radioligand binding 
[159], determining that inhibition of α9α10 nAChR with Vc1.1 reduces neuropathic pain in 
animal models [155, 177], determining brain regions involved in α6 mediated addiction 
pathways by electrophysiology [64] or in animal models by microinjection into a reward centre 
of the brain [99].  
While cone snails have produced a vast array of selective antagonists, a number of neuronal 
nAChR inhibitors have been identified from other plant and animal sources. A number of 
snakes (cobras, elapids) produce α-neurotoxins that act at neuronal nAChRs. α-Bungarotoxin 
is a 74 amino acid peptide, with 5 disulfide bridges identified in the venom of the Bungarus 
multicinctus snakes [34]. It was first found to block the neuromuscular junction, however 
subsequent studies found it also was also an α7 nAChR inhibitor. α-Bungarotoxin has provided 
an invaluable tool for examining neuronal function.  The toxin has been used to identify α7 
nAChR binding sites within the brain and changes to expression in response to various 
neurological pathologies by radioligand binding in brain slices [40, 77], to visualise α7 nAChR 
expression by tagging the toxin with a green fluorescent protein [158], to affinity isolate 
proteins using a biotinylated α-bungarotoxin [158], and to determine α7 nAChR meditated 
behavioral changes through microinjection into certain brain regions [1]. 
Methyllycaconitine is a deterpinoid alkaloid toxin produced by the Delphinium plant genus that 
acts as an antagonist at α7 nAChRs. It has been used extensively as a pharmacological tool to 
elucidate α7 nAChR mediated roles in memory, cognition, and depression as well as 
determining nAChR agonist mediated neurological effects [48, 66, 119, 180]. The toxin has 
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been used to elucidate α7 nAChR roles in animal models of Parkinson’s disease [109] and to 
determine mechanism of beta-amyloid neurotoxicity in in vitro models of Alzheimer’s [108].  
3.2.2 Acid-sensing ion channels 
Acid-sensing ion channels (ASICs) are pore-forming membrane proteins activated by 
extracellular protons, which are thought to be important in the detection of extracellular acidic 
pH during inflammation and ischemia. In mammals, six different ASIC subunits have been 
described (ASIC1a, ASIC1b, ASIC2a, ASIC2b, ASIC3, ASIC4) that combine to form either 
homo- or hetero-trimers. Toxins that target ASICs have been isolated from the venom of 
spiders, snakes and sea anemones, and have been pivotal in establishing the role of ASICs in 
ischemic stroke, neuronal inflammation, and pain [41]. 
The Texas coral snake toxin MitTx was the first toxin used to elucidate the role of ASIC1a and 
ASIC1b activation in pain. MitTx is a potent activator of ASIC1a (EC50 9 nM) and ASIC1b 
(EC50 23 nM), with at least 100-fold selectivity over the other ASIC subunits [18]. Intraplantar 
injection of MitTx (5 μM) causes spontaneous pain behaviors in mice, which are significantly 
attenuated in ASIC1-/- mice, confirming a role for ASIC1 in pain [18]. In addition, calcium 
imaging of mouse dorsal root ganglion (DRG) neurons with MitTx identified that functional 
ASIC1 is mainly co-expressed with TRPV1 (33%) and NF200 (53%), markers of small 
nociceptive and myelinated neurons, respectively [18]. MitTx was also used to determine the 
crystal structure of the chicken ASIC1a in the open state [10].  
Mambalgin-1, from the venom of the black mamba, is a potent inhibitor of ASIC1a and ASIC1b 
homomers and heteromers [58]. Administration of mambalgin-1 is antinociceptive in multiple 
mouse models of pain, revealing ASIC1 subunits as novel therapeutic targets for pain [56, 58]. 
Interestingly, the antinociceptive effects of mambalgin-1 are absent in ASIC1a-/- mice following 
intrathecal administration, but not peripheral administration, suggesting ASIC1a mediates the 
central effects and ASIC1b mediates the peripheral effects [56, 58].  
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APETx2, discovered from the venom of the sea anemone Anthopleura elegantissima, is a potent 
inhibitor of ASIC3 homomers (IC50 63 nM) and heteromers (IC50 100-2000 nM) [57]. APETx2 
has been used as a tool to elucidate the role of peripheral ASIC3 channels in acid-induced and 
inflammatory pain in rodents [54, 93]. However, APETx2 was later found to inhibit NaV1.8 
(IC50 2.6 μM), which may contribute to its antinociceptive effects in vivo [17].  
3.2.3 Transient receptor potential channels 
Transient Receptor Potential (TRP) channels are a large family of cation permeable channels 
that are activated by a variety of stimuli. Structurally, most TRP channels share six 
transmembrane spanning regions along with some degree of sequence homology [105]. TRP 
channels are further classed into seven sub-families; TRPC, TRPV, TRPA, TRPM, TRPN, 
TRPP and TRPPML [147].  While TRP channels are expressed in both excitable and non-
excitable cells, they play a distinct role in sensory neuro-signalling. Functionally, TRP channels 
are transducers that “sense” external stimuli, including mechanical, thermal and chemical 
stimuli [37, 38, 105, 147]. The result of TRP channel activation is cation influx leading to 
generator potentials, which can depolarise the membrane to trigger an action potential.   
Toxins have been utilised to delineate the function of TRP channels in neurons. TRPV1, one of 
the best studied TRP channel subtypes was in fact discovered, in part, due to its ability to bind 
capsaicin from chilli peppers [32]. TRPV1 is also activated by heat, thus the burning sensation 
associated with members of the Capsicum genus is caused by direct activation of TRPV1 by 
capsaicin. Indeed, many TRP channels are modulated by plant derived toxins including menthol 
(TRPM8; cold sensitive) and mustard oil (TRPA1; chemosensitive) (For review see; [178]). 
Recently, venom-derived toxins have shed light on TRP channels in vitro and in vivo [161]. 
This includes the double knot toxin DkTx from Ornithoctonus huwena (Chinese bird spider), 
which has provided insight into TRPV1 structure and gating [19]. Furthermore, investigation 
of centipede derived RhTx using electrophysiology, calcium imaging and in vivo pain behavior 
assays proffered new evidence on the mechanism of TRPV1 activation [191]. Although 
capsaicin remains a simple way to identify TRPV1, which is a marker commonly used to 
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identify nociceptive neurons, toxins continue to be critical for defining the difference between 
ligand-gated and stimulus-gated (ie. temperature) activation.  
Crotalphine, a venom-derived peptide from Crotalus durissus terrificus (South American 
rattlesnake) is a potent activator of TRPA1 (EC50 46 nM) [24]. Unlike other TRPA1 activators, 
such as allyl isothiocyanate from mustard oil that cause pain following topical application [91], 
intraplantar injection of crotalphine (10 μM) causes no pain behaviors in mice. Instead, 
crotalphine is analgesic in multiple inflammatory models of pain due to desensitization of the 
TRPA1 in vivo [24]. Crotalphine therefore provides a novel mechanism of targeting TRPA1 
that may be used for the development of new TRPA1 therapeutics.  
Toxins derived from the dinoflagellate Gambierdiscus toxicus, known as ciguatoxins (CTX), 
have been utilised to study the contribution of TRP channels in cold sensing [176]. P-CTX-1 
causes cold allodynia in patients suffering from ciguatera, a symptom that is recapitulated in 
rodents following intraplantar injection of P-CTX-1 (3-10 nM) [194].  It is therefore ideally 
placed to assess the contribution of ion channels and neuronal populations in cold sensing and 
pathological cold pain [12, 103].  Indeed, ciguatoxin-induced cold allodynia is mediated by 
TRPA1-expressing neurons, however P-CTX-1 itself does not directly activate TRPA1, but is 
a non-selective activator of NaV channels [83, 176]. This provides an example of how toxins 
can be used to provide unique insight into gross neuronal function. 
3.2.4 Ionotropic glutamate receptors 
Ionotropic glutamate receptors (iGluRs) are ligand-gated cation channels that open upon 
binding of the neurotransmitter glutamate, a key excitatory neurotransmitter in the CNS, to 
generate excitatory postsynaptic current. In humans, 18 iGluR subunits have been described 
that assemble into tetramers to form three receptor families, known as NMDA (N-methyl-D-
aspartate), AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid) and kainate 
receptors, originally named based on their sensitivity to agonists. In fact, toxins were pivotal in 
the discovery of AMPA receptors (formally known as quisqualic acid receptors) and kainate 
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receptors. Each iGluR subunit has a similar structural architecture, consisting of an extracellular 
N-terminal domain, an extracellular ligand-binding domain that binds glutamate, three 
membrane-spanning segments (M1, M3 and M4), and finally an intracellular C terminal domain 
[92]. Despite playing a key role in excitatory neurotransmission, relatively few toxins that 
selectivity act on iGluRs are reported in the literature.  
3.2.4.1 NMDA receptors 
NMDA receptors form tetramers from up to seven different subunits (GluN1, GluN2A-D, 
GluN3A-B). Unlike AMPA and kainate receptors, NMDA receptors require binding of both 
glycine (to GluN1 or GluN3) and glutamate (to GluN2) at distinct binding sites to open [135, 
171]. At the very least, functional NDMA receptors express one GluN1 and either GluN2 
subunits alone or a combination of GluN2 and GluN3 [42, 134]. The heterogeneity of the 
NMDA receptors based on this subunit array underpins its diverse role in neuronal function 
[135]. Intriguingly, while ligand binding is essential for channel opening, ion flux through 
NMDA receptors is also modulated by voltage-dependent binding of extracellular Mg2+ and 
Zn2+, which impede the passage of cations and in a sense, block the channel [117].  
Argiotoxin-636 (ArgTX-636), from the orb-weaver spider Argiope lobata, is a potent inhibitor 
of NMDA receptors containing the GluN2A or GluN2B subunits (IC50 5-9 nM), and has been 
used to probe the channel structure and mechanism of channel block [140, 146]. ArgTx-636 
interacts with the pore-loop M2 and transmembrane M3 sections, which form the core of the 
NMDA receptor, leading to steric block of cation flow [140]. The use of ArgTx-636 as a tool 
to study NMDA receptor function is limited by activity at the AMPA receptor subunit GluA1 
(IC50 77 nM), however analogues with improved selectivity have been developed [141].  
Conantokins are small linear peptides (17-24 amino acids) isolated from several different Conus 
species that inhibit NMDA receptors, with varying selectivity for the GluN2 subunits [104]. 
For example, the well-studied conantokin-G (Con-G; from Conus geographus) is selective for 
NMDA receptors containing the GluN2B subunit, inhibiting the receptor by competitively 
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binding with glutamate at the extracellular ligand binding domain of GluN2B [60, 186]. 
Differences in the selectivity of conantokins for GluN2B over GluN2A, GluN2C and Glu2D 
gives scope to rationally design selective inhibitors of these different NMDA receptor subunits 
to tease apart their role in neuronal function by pharmacological inhibition [173].  
Aberrant NMDA receptor function has been implicated in a variety of different neuronal 
abnormalities including Alzheimer’s disease, chronic pain, and ischemia/reperfusion injury 
[42, 135, 193]. Thus, the prospect of selective pharmacological inhibition of NMDA receptor 
subunits by toxins is an exciting therapeutic possibility.   
3.2.4.2 AMPA receptors 
AMPA receptors are the primary channel associated with fast excitatory neurotransmission in 
the CNS [74, 171]. They are heterotetramers formed by up to four subunits (GluA1-4), with 
GluA1/GluA2 heterotetramers most abundant in the CNS [20, 75]. The presence of the GluA2 
subunit renders AMPA receptors impermeable to Ca2+ due to the presence of an additional 
positive charge in the pore (R607) [84]. Quisaqualic acid, from the seeds of Quisqualis indica, 
was originally used to identify the AMPA receptor, but was superseded by the agonist AMPA, 
due to poor selectivity over kainate and metabotropic glutamate receptors [160].  
Con-ikot-ikot, a large 86 amino acid peptide isolated from the venom of Conus striatus, 
selectively enhances AMPA receptor currents by blocking desensitization, and is active at all 
four subunits (GluA1-4) [181]. Con-ikot-ikot has no detectable activity on kainate receptors 
containing GluK2 or NMDA receptors containing GluN1/GluN2A, suggesting it is selective 
for AMPA receptors, although activity at other iGluR subunits remains to be confirmed. Con-
ikot-ikot recently proved useful for resolving the crystal structure of the GluA2 AMPA receptor 
in the activated state, interacting with the extracellular ligand binding domain [36].  
3.2.4.3 Kainate receptors 
Like the AMPA receptor, the kainate receptor was discovered due to activation by kainate, a 
naturally occurring neurotoxin isolated from the red algae Digenea simplex. Kainate receptors 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 22 
are tetramers formed by one or more combinations of five subunits (GluK1-5), with GluK1-3 
subunits capable of forming functional homo- or hetero-tetrameric channels, while GluK4 and 
GluK5 require heterotetrameric assembly with one of the GluK1-3 subunits [86, 121]. 
Compared to NMDA and AMPA receptors, less is known about kainate receptors due to a lack 
of selective pharmacological probes. Kainate and the structural analogue domoate, also isolated 
from marine algae, interact with the glutamate-binding site to activate kainate receptors (and 
less potently AMPA receptors), with subtle differences in activity and selectivity at GluK1, 
GluK2 and GluK3 [86, 157]. The agonist 5-iodowillardiine, isolated from the seeds of Acacia 
and Mimosa species, is a selective agonist of the GluK1 subunit (EC50 0.21 μM), with no effect 
at GluK2 and GluK3 at concentrations > 300 μM [7, 168].  
3.2.5 GABAA receptors 
The endogenous ligand of the GABAA receptor is γ-aminobutyric acid (GABA), the major 
inhibitory neurotransmitter in the CNS. Upon GABA binding, GABAA receptors open to allow 
the influx of chloride ions, ultimately causing hyperpolarisation of the neuron and rapidly 
inhibiting synaptic transmission in the brain. Structurally, GABAA receptors are pentamers 
arranged to form a central pore, made up of 19 subunits α1-6, β1-3, γ1-3, δ, ε, θ, π and ρ1-3, 
with the majority of heteromers consisting of two α subunits, two β subunits, and one other 
subunit [118, 162]. GABAA receptors are the target of the barbiturate and benzodiazepine 
classes of drugs, thus they have clinical potential for the treatment of many neurological 
disorders.  
Initially, bicuculline and picrotoxin, alkaloid toxins isolated from plants known to cause 
convulsions, were discovered to be antagonists of the GABAA receptor and were used to the 
study its function [90, 126]. Many venom-based toxins with activity at GABAA receptors have 
also been reported, including α-bungarotoxin, α-cobratoxin and the α-conotoxin ImI, however 
these toxins also act at nAChRs, as both receptors belong to the pentameric Cys-loop 
superfamily of ligand-gated ion channel receptors [98]. Recently, two toxins named MmTX1 
and MmTX2, isolated from the venom of the Costa Rican coral snake, were found to potently 
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modulate GABAA receptors, without displacing the binding of several nAChR ligands to rat 
brain synaptosomes, suggesting selectivity for GABAA receptors [152]. Both toxins 
allosterically increased the GABAA receptor affinity for agonists, in a similar manner to 
benzodiazepines, making them useful drug leads to develop novel therapeutics that modulate 
GABAA receptors.  
4. Limitations of using toxins as probes 
Despite being highly potent for a molecular target of interest, the main limitation of toxins is 
the potential for off-target activity. Off-target activity may occur within channels or receptors 
of the same class due to high sequence homology or it may occur within different ion channel 
or receptor classes due to structural homology. Promiscuous activity is particularly evident 
amongst venom-derived peptides that target the voltage-sensing domain of voltage-gated ion 
channels, with venom-derived peptides from spiders often reported to have activity at NaV, KV 
and CaV channels [16, 65, 132, 164]. However, it should be noted that compared to most other 
probes, including synthetic small molecules and endogenous ligands, toxins in general remain 
to be the most selective modulators available for voltage-gated and ligand-gated ion channels.  
Often the use of a toxin as a tool may be limited by the amount of material available to 
researchers. This is because many toxins are difficult to produce synthetically or recombinantly 
in large quantities and purification from the original biological source may not be possible. An 
example of this is the alkaloid NaV channel activator batrachotoxin, which was originally 
purified from the skin glands of the now endangered poison dart frog [45]. Difficulties in 
chemical synthesis of batrachotoxin, which were only recently overcome [110], have so far 
limited the widespread use of this toxin as a pharmacological tool.  
Knowing the effective concentration of a toxin at the target of interest can be problematic, 
particularly in ex vivo and in vivo studies. Sometimes, the concentration required to produce a 
functional response far exceeds the potency of the toxin determined by in vitro functional 
assays. Examples of this include the ASIC1 activator MitTx (EC50 9-23 nM), the NaV1.1 
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activator δ-theraphotoxin-Hm1a (EC50 38 nM) and the KV1.1, KV1.2 and KV1.6 inhibitor α-
dendrotoxin (EC50 1-25 nM), which need to be administered by intraplantar injection at 
concentrations of 5 μM, 5 μM, and 100 μM, respectively, to elicit pain behaviors in mice [18, 
116, 132]. This therefore can make it difficult to determine if the administered concentration is 
indeed selective for the target of interest based on in vitro selectivity data, and may require the 
use of knockout animals (when available) to confirm target specificity.  
5. Conclusion 
Toxins are a structurally and functionally diverse group of compounds that interact with many 
different neuronal ion channels and receptors.  From the discovery of novel molecular targets, 
to the determination of ion channel and receptor structure and function, there is no doubt that 
toxins have and will continue to be essential tools to probe neuronal function. Advances in 
high-throughput electrophysiology and fluorescence-based assays, in combination with 
improved proteomics, transcriptomics and mass spectrometry, will undoubtedly lead to the 
discovery of novel toxins with activity at neuronal ion channels and receptors currently lacking 
selective pharmacological probes [142, 151]. In addition, improvements in chemical synthesis 
and recombinant expression technology of peptide-based toxins will also increase the quantity 
of toxins available to be used in functional studies in the future [172].  
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Figure Legends 
Figure 1. Overview of the experimental techniques commonly used to assess toxin effects on 
neuronal function.  
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